The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
121243555 12124355 5 F 201602 20160917 20160229 20160922 EXP CA-SA-2016SA039263 AVENTIS 46.00 YR A F Y 80.00000 KG 20160922 MD CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
121243555 12124355 1 PS FABRAZYME AGALSIDASE BETA 1 Intravenous drip Y E4025Y07 103979 1 MG/KG POWDER FOR SOLUTION FOR INFUSION QOW
121243555 12124355 2 SS FABRAZYME AGALSIDASE BETA 1 Intravenous drip Y E5004Y05 103979 1 MG/KG POWDER FOR SOLUTION FOR INFUSION QOW
121243555 12124355 3 SS FABRAZYME AGALSIDASE BETA 1 Intravenous drip Y E4025Y13 103979 1 MG/KG POWDER FOR SOLUTION FOR INFUSION QOW
121243555 12124355 4 SS FABRAZYME AGALSIDASE BETA 1 Intravenous drip Y E5020Y02 103979 1 MG/KG POWDER FOR SOLUTION FOR INFUSION QOW
121243555 12124355 5 SS FABRAZYME AGALSIDASE BETA 1 Intravenous drip Y E5023Y013 103979 1 MG/KG POWDER FOR SOLUTION FOR INFUSION QOW
121243555 12124355 6 SS FABRAZYME AGALSIDASE BETA 1 Intravenous drip Y E5020Y08 103979 1 MG/KG POWDER FOR SOLUTION FOR INFUSION QOW
121243555 12124355 7 SS TOPIRAMATE. TOPIRAMATE 1 Unknown Y UNKNOWN 0 50 MG QD
121243555 12124355 8 SS TOPIRAMATE. TOPIRAMATE 1 Unknown Y UNKNOWN 0
121243555 12124355 9 C REACTINE CETIRIZINE HYDROCHLORIDE 1 Oral 0 10 MG
121243555 12124355 10 C TYLENOL ACETAMINOPHEN 1 Oral 0 500 MG
121243555 12124355 11 C PLAVIX CLOPIDOGREL BISULFATE 1 0 75 MG QD
121243555 12124355 12 C VITAMIN B12 CYANOCOBALAMIN 1 DOSE: 1000 MICRO 0 QD

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
121243555 12124355 1 Fabry's disease
121243555 12124355 2 Fabry's disease
121243555 12124355 3 Fabry's disease
121243555 12124355 4 Fabry's disease
121243555 12124355 5 Fabry's disease
121243555 12124355 6 Fabry's disease
121243555 12124355 9 Premedication
121243555 12124355 10 Premedication

Outcome of event

Event ID CASEID OUTC COD
121243555 12124355 DS

Reactions reported

Event ID CASEID DRUG REC ACT PT
121243555 12124355 Constipation
121243555 12124355 Delayed sleep phase
121243555 12124355 Eye disorder
121243555 12124355 Fatigue
121243555 12124355 Feeling abnormal
121243555 12124355 Irritability
121243555 12124355 Malaise
121243555 12124355 Pain in extremity
121243555 12124355 Paraesthesia

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
121243555 12124355 1 20120627 0
121243555 12124355 2 20120627 0
121243555 12124355 3 20120627 0
121243555 12124355 4 20120627 0
121243555 12124355 5 20120627 0
121243555 12124355 6 20120627 0
121243555 12124355 7 20160203 20160228 0